Target intelligence / Profile preview

Alpha-synuclein aggregate (α-syn)

Target
α-syn
Molecular classification
Intrinsically disordered protein, Amyloidogenic protein, Misfolded protein aggregate
01

Overview

Alpha-synuclein is a presynaptic protein that normally regulates neurotransmitter release and vesicle trafficking, but its pathological aggregation is the hallmark of synucleinopathies such as Parkinson's disease and Dementia with Lewy bodies (UniProt P37840). The transition from soluble monomers to toxic oligomers and insoluble fibrils leads to neuronal dysfunction, impaired proteostasis, and cell death. As a therapeutic target, drug development focuses on preventing the misfolding process, neutralizing toxic extracellular species, or accelerating the clearance of existing aggregates. Current clinical candidates include monoclonal antibodies like Prasinezumab designed to intercept the cell-to-cell spread of pathological protein and small molecules like Anle138b that inhibit oligomer formation. Success in targeting these aggregates is heavily reliant on early detection through emerging biomarkers like seed amplification assays, which can identify misfolded proteins in cerebrospinal fluid before significant neurodegeneration occurs.

Other names
SNCANACPNon-amyloid component of plaque precursorAlpha-synuclein oligomerLewy body proteinAlpha-synuclein filament
02

Mechanism of action

Therapeutic strategies include monoclonal antibodies that bind to and promote the clearance of extracellular aggregates, small molecules that inhibit the nucleation and elongation of oligomers, and agents that enhance the lysosomal or autophagic degradation of intracellular protein clumps.

03

Biological functions

Synaptic vesicle traffickingNeurotransmitter release regulationDopamine metabolismDNA repairMicrotubule stabilization
04

Disease associations

Parkinson's diseaseDementia with Lewy bodiesMultiple system atrophyPure autonomic failureNeurodegenerative disease
05

Safety considerations

Potential disruption of normal synaptic vesicle recyclingNeuroinflammationBlood-brain barrier penetration limitationsImmunogenicity of monoclonal antibodiesOff-target binding to other synuclein family members
06

Interacting drugs

6 more in the full profile.

07

Biomarkers

Alpha-synuclein Seed Amplification Assay (αSyn-SAA)CSF total alpha-synucleinPhosphorylated alpha-synuclein (pS129)Skin biopsy alpha-synuclein deposits

Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.

Beyond the preview

Go deeper on Alpha-synuclein aggregate (α-syn).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alpha-synuclein aggregate (α-syn).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call